Journal
SCIENTIFIC REPORTS
Volume 9, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-019-47243-z
Keywords
-
Categories
Funding
- Kidney Research UK [PDF_003_20151124, RP_006_20180227]
- Northern Counties Kidney Research Fund
- Medical Research Council [MR/M012212/1]
- DiMEN Studentship
- Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
- MRC [MC_PC_17168, MR/M012212/1, 1934315] Funding Source: UKRI
- Kidney Research UK [RP_006_20180227, ST_001_20171120] Funding Source: researchfish
- Medical Research Council [MR/M012212/1] Funding Source: researchfish
Ask authors/readers for more resources
Joubert syndrome (JBTS) is an incurable multisystem ciliopathy syndrome. The most commonly mutated gene in JBTS patients with a cerebello-retinal-renal phenotype is CEP290 (alias JBTS5). The encoded CEP290 protein localises to the proximal end of the primary cilium, in the transition zone, where it controls ciliary protein composition and signalling. We examined primary cilium structure and composition in fibroblast cells derived from homozygous and compound heterozygous JBTS5 patients with nonsense mutations in CEP290 and show that elongation of cilia, impaired ciliogenesis and ciliary composition defects are typical features in JBTS5 cells. Targeted skipping of the mutated exon c.5668 G > T using antisense oligonucleotide (ASO) therapy leads to restoration of CEP290 protein expression and functions at the transition zone in homozygous and compound heterozygous JBTS5 cells, allowing a rescue of both cilia morphology and ciliary composition. This study, by demonstrating that targeted exon skipping is able to rescue ciliary protein composition defects, provides functional evidence for the efficacy of this approach in the treatment of JBTS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available